Kyorin unveils new oral dose plant
Japan's Kyorin Pharmaceuticals plans to invest some 8 billion yen
(€62.5m) in a new facility to produce tablet and capsule
S-P cuts jobs to slash costs
Schering-Plough has lowered its financial forecasts for the second
time and unveiled a fresh round of cost cutting in an attempt to
stabilise its finances.
Amcor expansion continues apace
Australian packaging group Amcor has entered into a A$330 million
(€198m) agreement to buy Rexam's healthcare flexibles packaging
business and will also buy out Danisco and Ahlstrom's 28.1 per cent
minority stake in its...
Focus shift for Fugensoft
US e-business software company Fugensoft has revamped its product
range, introducing a suite of new products and a change of focus,
to meet the needs of the biotech and pharmaceutical industry 'where
there is a huge need for...
Capacity utilisation ups profit margins
Top pharmaceutical manufacturing plants strive to achieve efficient
operations that result in increased profitability as well as
superior product quality and satisfied customers. These are the
findings of a new study from market research...
Fisher extends Perbio offer
Fisher Scientific has extended its SK5.3 billion (€573m) offer for
Perbio Science after failing to win the support of more than 90 per
cent of Perbio's investors.
The end of the blockbuster?
A new report from Datamonitor predicts the end of the
pharmaceutical industry's blockbuster product model, pointing to a
dramatic shortfall in growth rates for billion dollar-plus products
out to 2008.
Xenova plans to buy KS Bio
Xenova has become the latest company to ride the wave of
consolidation sweeping the UK biotechnology industry by offering to
buy KS Biomedix.
Bayer's Walothen subsidiary sold off
German chemicals and drugs company Bayer has said that it plans to
sell its subsidiary Walothen to Finland's Wihuri as part of an
ongoing restructuring of its portfolio.
Daicel forges US links to expand business
Daicel has entered into an agreement with Thesis Chemistry in a
deal which will see the two companies collaborate in the area of
chiral process manufacturing.
Degussa sees sales, profits slump in second quarter
Degussa follows its peers in the speciality chemicals industry by
posting weak interim results held back by currency factors, raw
material costs and lower demand.
China Pharma triples net profit
China Pharma sees revenues and net profits soar in first half, but
analysts say bulk drugs may come under pricing pressure going
Swedish biotechs link up
Pyrosequencing, a genetic analysis systems manufacturer, has
acquired a 94.1 per cent stake in chemical synthesis concern
Personal Chemistry in an all-stock transaction.
FTC takes on alleged process control software monopoly
The US FTC has taken issue with the merger between Aspen Technology
and Hyprotech in 2002, alleging that it gave the combined firm a
too-dominant position in process control software.
BASF sees no recovery until fourth quarter
BASF, the world's largest chemicals company, has said that it will
expand an ongoing restructuring program in North America after
reporting lower-than-expected second-quarter sales and profits.
Caliper sheds jobs after Zymark buy
Caliper has cut 9 per cent of its staff as part of a restructuring
exercise following its $72 million acquisition of lab automation
Bayer sales on the slide in second quarter
Bayer has reported a decline in net profits for the second quarter
of 2003, with analysts expressing concerns that litigations costs
could hold back full-year earnings.
Cambrex sells non-core business
Cambrex plans to sell off its Rutherford Chemicals business for $64
million (€56m) to allow it to focus on its human health and
New contract manufacturer buys plant
KBI BioPharma, a start-up biopharma contract manufacturer, has
signed an agreement to buy a facility in North Carolina that could
be online in 6-9 months.
Cobra signs cancer vaccine production deal
Cobra Biomanufacturing has signed an agreement to supply Advaxis
with clinical and commercial supplies of its Listeria
monocytogenes-based cancer vaccine.
Irish meeting on manufacturing excellence
A conference on batch process automation and asset management in
the pharmaceutical industry is scheduled to take place in Cork,
Ireland, on 22-23 October.
Recordati planning pharmachem sale
Italy's Recordati has said that it plans to sell off its
pharmaceutical chemical activities over the next few months in
order to concentrate on pharmaceuticals.
Interims confirm turnaround at Flamel
French drug delivery specialist Flamel posts a healthy rise in
revenues in the second quarter, boosted by milestone payments from
GSK and Servier.
Bayer contract aids Probitas expansion
Grifols has signed an agreement with the Biological Products
division at Bayer Healthcare in the USA to supply pharmaceutical
Biotech merger wave gathers up KS Bio
KS Biomedix has confirmed that it is in negotiations that may lead
to a merger and add to the mini-wave of consolidation sweeping over
the UK industry.
Argonaut exits HPLC business
Argonaut sells its HPLC business to Grace Vydac as it refocuses on
supplying consumables for companies working on drug discovery.
Reports reduced losses in first half.
Amersham comes in low, but on track
Amersham trims its 2003 profit outlook again after reporting lower
interim sales and profits, but points to currency effects and the
underlying strength of the business
Roche buys its way out of diagnostics trouble
Roche has moved to settle its long-running legal dispute with
USA-based Igen by acquiring the firm in a deal valued at around
$1.4 billion (€1.22bn).
Pliva opens new unit in USA
Pliva has continued its rapid expansion with the opening of a new
R&D facility in the USA that will carry out formulation work on
Funguard capacity to swell on sales growth
Fujisawa has decided to build a new formulation plant for its
recently launched antifungal Funguard with a capital investment of
Y3.8 billion (€28m).
Pharma holds back life sciences at DSM
DSM reports a disappointing set of second quarter results and says
it is unlikely to meet its 2002 operating profit level this year;
the group blames weaker demand for its products and negative
currency factors. Restructuring drive...
Baxter wins court order in Bayer espionage case
A judge has ordered an employee at Bayer's US subsidiary to hand
files over to the court in a lawsuit brought by Baxter alleging
InnaPhase completes Beckman LAO buy
InnaPhase has completed the transaction of Beckman Coulter's
Laboratory Automation Operations (LAO) that was announced in May of
LGC expands pharma business outside UK
LGC has acquired Germany's Mikromol, a specialist in pharmaceutical
impurities and metabolites used as reference materials, to create
its first non-UK lab.
Baxter accuses former employee of espionage
Baxter has filed a lawsuit in the USA alleging that one of its
former employees provided proprietary manufacturing information to
rival company Bayer.
Pharma's focus on growth "unsustainable" says report
The pharmaceutical industry is failing to increase efficiencies in
core areas of its business - such as clinical trials and sales -
because of an enormous pressure from investors to drive revenues,
according to Datamonitor.
Lonza revamp comes too late for first-half figures
The difficulties facing Lonza came into clear focus today as the
company published its half-year results, with sales down across its
custom manufacturing, organic chemicals and polymers businesses.
BASF buys pharma chemical firm
Chemical major BASF has expanded the range of products it offers to
pharmaceutical clients with the $65 million (€58m) purchase of
Callery Chemical from Mine Safety Appliances.
Millipore 2Q sales up but biotech static
Millipore has reported buoyant sales growth in the second quarter
of this year but was let down by a lacklustre showing from its
biotechnology division, held up as one of the key drivers of future
Akzo results better than expected
Akzo Nobel's second-quarter results reveal increasing pressure on
its drugs business and lead to speculation that it may consider a
Galen says takeover talks break down
Galen Holdings of the UK has called an end to talks with an unnamed
buyer, thought to have been US generics specialist Barr
Sheep cull follows staff cuts at PPL
Scotland's PPL has started a mass slaughter of its flock of sheep
engineered to produce alpha-1 antitrypsin in their milk. The cull
could spell the end of the firm's ambitions in transgenic
India's Wockhardt buys CP Pharma
India's Wockhardt has acquired CP Pharmaceuticals in a deal valued
at £10.9 million (€15.6m) that grows the Indian firm's UK market
Celltech books long run at Lonza facility
Lonza Biotec is to manufacture PEGylated antibody fragment-based
drugs for Celltech under the terms of a new agreement between the
two companies. The two companies have also reached an agreement on
a prior deal relating to Celltech's...
Crucell revenues slide in 2Q
Dutch biotechnology company Crucell has reported a decline in
revenues for the second quarter of 2003, down 62 per cent to €1.1
Denmark booms on back of US exports
Danish pharmaceutical companies increased their sales to overseas
countries by 20 per cent in the first four months of this year
compared with the same period of 2002, according to Invest In
Merck cuts activities in France
Merck KGaA has trimmed down its operations in France with the
closure of a site at Lacassagne focusing on preclinical R&D and
Joint venture takes Profile towards US presence
A joint venture between UK inhaler specialist Profile and generics
company Breath opens up a new market valued at $1 billion
€2bn credit facility for Degussa
Germany's third largest chemical company has raised € 2 bn of
credit lines by means of a syndicated facility with a group of
leading international banks.
Chiron collars PowderJect
Chiron's has completed its acquisition of UK vaccine and drug
delivery specialist PowderJect, making it the second-largest
manufacturer of flu vaccines worldwide.